SCOPUS 정보 검색 플랫폼

British Journal of Pharmacology

Volumn 169, Issue 8, 2013, Pages 1647-1651

Emerging therapeutic aspects in oncology

(1) MacEwan, David J a

a UNIVERSITY OF LIVERPOOL (United Kingdom)

Author keywords

biologics; chemotherapy; drug resistance; TKI; tumor

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; ANTIANDROGEN; ANTIBIOTIC AGENT; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BELIMUMAB; BEVACIZUMAB; CARBOPLATIN; CATUMAXOMAB; CISPLATIN; DOXORUBICIN; DUPILUMAB; GEMTUZUMAB; GONADOTROPIN DERIVATIVE; IMATINIB; INFLIXIMAB; IPILIMUMAB; METHOTREXATE; MONOCLONAL ANTIBODY; MUSTARD GAS; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; TAMOXIFEN; TRASTUZUMAB; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG; VINCA ALKALOID;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CELL GROWTH; CELL MEMBRANE; CHILDHOOD LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CRITICALLY ILL PATIENT; CRYOSURGERY; DRUG TARGETING; GROWTH RATE; HISTORY OF MEDICINE; HUMAN; LEUKEMIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MYELOMA; NANOTECHNOLOGY; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOLOGY; OVERALL SURVIVAL; PHARMACOGENOMICS; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SOLID TUMOR; SURVIVAL RATE;

BIOLOGICS; CHEMOTHERAPY; DRUG RESISTANCE; TKI; TUMOR;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 84881357878 PISSN: 00071188 EISSN: 14765381 Source Type: Journal
DOI: 10.1111/bph.12304 Document Type: Review

Times cited : (3)

References (11)

1
- 84881342288
- Curcumin: An orally bioavailable blocker of TNF and other pro-inflammatory biomarkers
- Aggarwal BB, Gupta SC, Sung B, (2013). Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol 169: 1672-1692.
- (2013) Br J Pharmacol , vol.169 , pp. 1672-1692
- Aggarwal, B.B.¹ Gupta, S.C.² Sung, B.³

2
- 84881357858
- Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer
- Curtin NJ, (2013). Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer. Br J Pharmacol 169: 1745-1765.
- (2013) Br J Pharmacol , vol.169 , pp. 1745-1765
- Curtin, N.J.¹

3
- 83555170281
- Targetted CML treatments
- Heasman S, Small M, MacEwan DJ, (2011). Targetted CML treatments. Br Oncol Pharm Assoc J. 3: 11-15.
- (2011) Br Oncol Pharm Assoc J. , vol.3 , pp. 11-15
- Heasman, S.¹ Small, M.² MacEwan, D.J.³

4
- 79958852971
- Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias
- Kvinlaug BT, Chan WI, Bullinger L, Ramaswami M, Sears C, Foster D, et al. (2011). Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Res 71: 4117-4129.
- (2011) Cancer Res , vol.71 , pp. 4117-4129
- Kvinlaug, B.T.¹ Chan, W.I.² Bullinger, L.³ Ramaswami, M.⁴ Sears, C.⁵ Foster, D.⁶

5
- 0036184885
- TNF ligands and receptors: A matter of life and death
- MacEwan DJ, (2002). TNF ligands and receptors: a matter of life and death. Br J Pharmacol 135: 855-875.
- (2002) Br J Pharmacol , vol.135 , pp. 855-875
- MacEwan, D.J.¹

6
- 84930538669
- Emerging therapy targeting Bruton's tyrosine kinase (BTK): Potential for ibrutinib and other BTK inhibitors
- (in press).
- MacEwan DJ, Bowles KM, Rushworth SA, (2013). Emerging therapy targeting Bruton's tyrosine kinase (BTK): potential for ibrutinib and other BTK inhibitors. Drugs Future. (in press).
- (2013) Drugs Future
- MacEwan, D.J.¹ Bowles, K.M.² Rushworth, S.A.³

7
- 84881338743
- Death receptors as targets in cancer
- Micheau O, Shirley S, Dufour F, (2013). Death receptors as targets in cancer. Br J Pharmacol 169: 1723-1744.
- (2013) Br J Pharmacol , vol.169 , pp. 1723-1744
- Micheau, O.¹ Shirley, S.² Dufour, F.³

8
- 84894507237
- The late William Blair-Bell, M.D., F.R.C.S
- Nicholls AG, (1936). The late William Blair-Bell, M.D., F.R.C.S. Can Med Assoc J 34: 683-684.
- (1936) Can Med Assoc J , vol.34 , pp. 683-684
- Nicholls, A.G.¹

9
- 84881338758
- To breathe or not to breathe: The haematopoietic stem/progenitor cells dilemma
- Piccoli C, Agriesti F, Scrima R, Falzetti F, Di Ianni M, Capitanio N, (2013). To breathe or not to breathe: the haematopoietic stem/progenitor cells dilemma. Br J Pharmacol 169: 1652-1671.
- (2013) Br J Pharmacol , vol.169 , pp. 1652-1671
- Piccoli, C.¹ Agriesti, F.² Scrima, R.³ Falzetti, F.⁴ Di Ianni, M.⁵ Capitanio, N.⁶

10
- 84881326118
- That which does not kill me makes me stronger; Combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance
- Sale MJ, Cook SJ, (2013). That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance. Br J Pharmacol 169: 1708-1722.
- (2013) Br J Pharmacol , vol.169 , pp. 1708-1722
- Sale, M.J.¹ Cook, S.J.²

11
- 84881360762
- Targeting survival pathways in chronic myeloid leukaemia stem cells
- Sinclair A, Latif AL, Holyoake TL, (2013). Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol 169: 1693-1707.
- (2013) Br J Pharmacol , vol.169 , pp. 1693-1707
- Sinclair, A.¹ Latif, A.L.² Holyoake, T.L.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.